NDA 219208 · Novartis
Vanrafia
Atrasentan Hydrochloride · Oral
NovelAccelerated approvalCDER novel approval, Apr 2, 2025: To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Apr 2, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
10 Phase 3, 2 recruiting
FAERS reports
101
30 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY VANRAFIA is contraindicated for use in pregnant patients; it may cause major birth defects based on animal data [see Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1)] . Exclude pregnancy prior to initiation of treatment with VANRAFIA. Advise use of effective contraception before the initiation of treatment, during treatment, and for two weeks after discontinuation of treatment with VANRAFIA. Stop VANRAFIA as soon as possible if the patient becomes pregnant [see Dosage and Administration (2.1), Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)] . WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. VANRAFIA may cause major birth defects if used during pregnancy ( 4.1 , 5.1 , 8.1 ) Exclude pregnancy before start of treatment. ( 2.1 ,...
What it is approved for
From the label in effect Jun 12, 2026.
VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria [see Clinical Studies (14.1)] . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. VANRAFIA is an endothelin receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. ( 1 ) This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. ( 1 )
Mechanism: Atrasentan is an ET A receptor antagonist (Ki = 0.034 nM) with >1800-fold selectivity for the ET A receptor compared to the endothelin type B receptor (Ki = 63.3 nM). Endothelin (ET)-1 is thought to contribute to the pathogenesis of IgAN via the ET A R.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 2, 2025 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalLabelLetterReview
1 products under this application
- VANRAFIA · ATRASENTAN HYDROCHLORIDE EQ 0.75MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Atrasentan" as an intervention, any sponsor and status, largest first.
- Study Of Diabetic Nephropathy With AtrasentanPivotal-lookingTerminated
AbbVieAbbVie (ABBV)
NCT01858532 · 5,107 participants · Start May 17, 2013 · Primary completion Mar 29, 2018
Drug: Atrasentan; Placebo · For: Diabetic Nephropathy
- S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapyPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00134056 · 1,038 participants · Start Aug 2006 · Primary completion Feb 2016
Drug: atrasentan hydrochloride; docetaxel and 1 more · For: Metastatic Cancer; Prostate Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 554 sites in all
- A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate CancerPivotal-lookingCompleted
AbbottIndustry
NCT00036543 · 1,000 participants · Start May 2001
Drug: Atrasentan · For: Prostate Cancer
Sites: Homewood, Alabama; Anchorage, Alaska; Tucson, Arizona · 232 sites in all
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate CancerPivotal-lookingCompleted
AbbottIndustry
NCT00036556 · 941 participants · Start Jun 2001
Drug: Atrasentan · For: Prostatic Neoplasms
Sites: Homewood, Alabama; Anchorage, Alaska; Tucson, Arizona · 234 sites in all
- Atrasentan in Patients With IgA NephropathyPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04573478 · 404 participants · Start Dec 11, 2020 · Primary completion Apr 14, 2028
Drug: Atrasentan; Placebo and 1 more · For: IgA Nephropathy; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Alhambra, California; Glendale, California · 135 sites in all
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07850752 · 340 participants (planned) · Start Nov 11, 2026 · Primary completion Sep 17, 2028
Drug: zigakibart; atrasentan and 1 more · For: IgA Nephropathy (IgAN)
Sites: Huntsville, Alabama; Fremont, California; Newark, Delaware · 11 sites in all
- Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical FailurePivotal-lookingCompleted
AbbottIndustry
NCT00038662 · 200 participants · Start May 2002
Drug: Atrasentan · For: Prostatic Neoplasms
Sites: Homewood, Alabama; Anchorage, Alaska; Little Rock, Arkansas · 40 sites in all
- Correlation of Endothelial Function and Early Coronary Artery Disease in HumansPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00271492 · 200 participants · Start Jul 2001 · Primary completion Jun 2006
Drug: Atrasentan; Atrasentan and 1 more · For: Endothelial Dysfunction
Sites: Rochester, Minnesota
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective9
- fatigue9
- dizziness6
- nausea6
- peripheral swelling6
- product dose omission issue6
- swelling6
- blood creatinine increased5
- oedema5
- rash5
- renal impairment5
- anaemia4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2025 | 46 |
| 2026 | 44 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Atrasentan in Patients with IgA Nephropathy.
Heerspink HJL, Jardine M, Kohan DE, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Heerspink HJL, Jardine MJ, Kohan DE, et al. · Lancet 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, et al. · Lancet 2019 · Multicenter Study, Randomized Controlled Trial
- The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC, Stefansson BV, Batiushin M, et al. · Nephrol Dial Transplant 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial.
Heerspink HJL, Noronha IL, Górriz JL, et al. · J Am Soc Nephrol 2026 · Randomized Controlled Trial
- Novel Therapies for Kidney Disease in People With Diabetes.
Khurana N, James S, Coughlan MT, et al. · J Clin Endocrinol Metab 2022 · Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.